Effect of etanercept (enbrel) on interleukin 6, tumor necrosis factor ", and markers of immune activation in HIV-infected subjects receiving interleukin 2

Beverly E. Sha, Debra M. Ogata-Arakaki, Lawrence Fox, Scharla Estep, Alejo Erice, Patrick Kilgo, Richard B Pollard, Lynne Bancroft, Michael M. Lederman, Hernan Valdez, Rebecca S. Gelman, Alan L. Landay, Jan Agosti, Ronald Mitsuyasu, Richard B. Pollard, Donna Mildvan, Ann Namkung

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

The effect of etanercept, a soluble p75 tumor necrosis factor (TNF) receptor:Fc fusion protein (Enbrel; Immunex, Seattle, WA) on plasma cytokines was evaluated in 11 HIV-infected subjects receiving highly active antiretroviral therapy (HAART) for 28 weeks with or without subcutaneous or intravenous recombinant human interleukin 2 (rhIL-2). Plasma IL-6 and C-reactive protein (CRP) levels increased after rhIL-2 treatment. Etanercept pretreatment attenuated these increases. Median plasma IL-6 levels were 20.29 pg/ml 4 days after rhIL-2 and 7.87 pg/ml 4 days after etanercept and rhIL-2 (p = 0.22); median CRP levels were 78.73 and 46.16 μg/ml, respectively (p = 0.03). An effect on TNF bioactivity could not be assessed as all measurements were below limits of detection. No significant changes were seen in temperature or plasma levels of IL-4, IL-l0, IL-12, interferon γ, or HIV-1 RNA levels. All subjects had undetectable or low-level HIV-1 RNA levels before etanercept dosing. One subject died; however, her death was thought to be unrelated to etanercept. Pretreatment with etanercept may blunt activation of IL-6 and CRP expression induced by rhIL-2. The safety and utility of etanercept in HIV-infected persons should be explored further.

Original languageEnglish (US)
Pages (from-to)661-665
Number of pages5
JournalAIDS Research and Human Retroviruses
Volume18
Issue number9
DOIs
StatePublished - 2002
Externally publishedYes

Fingerprint

Interleukin-2
Interleukin-6
Tumor Necrosis Factor-alpha
Biomarkers
HIV
C-Reactive Protein
HIV-1
RNA
Etanercept
Tumor Necrosis Factor Receptors
Highly Active Antiretroviral Therapy
Interleukin-12
Interleukin-4
Interferons
Limit of Detection
Cytokines
Safety
Temperature
Proteins

ASJC Scopus subject areas

  • Immunology
  • Virology

Cite this

Effect of etanercept (enbrel) on interleukin 6, tumor necrosis factor ", and markers of immune activation in HIV-infected subjects receiving interleukin 2. / Sha, Beverly E.; Ogata-Arakaki, Debra M.; Fox, Lawrence; Estep, Scharla; Erice, Alejo; Kilgo, Patrick; Pollard, Richard B; Bancroft, Lynne; Lederman, Michael M.; Valdez, Hernan; Gelman, Rebecca S.; Landay, Alan L.; Agosti, Jan; Mitsuyasu, Ronald; Pollard, Richard B.; Mildvan, Donna; Namkung, Ann.

In: AIDS Research and Human Retroviruses, Vol. 18, No. 9, 2002, p. 661-665.

Research output: Contribution to journalArticle

Sha, BE, Ogata-Arakaki, DM, Fox, L, Estep, S, Erice, A, Kilgo, P, Pollard, RB, Bancroft, L, Lederman, MM, Valdez, H, Gelman, RS, Landay, AL, Agosti, J, Mitsuyasu, R, Pollard, RB, Mildvan, D & Namkung, A 2002, 'Effect of etanercept (enbrel) on interleukin 6, tumor necrosis factor ", and markers of immune activation in HIV-infected subjects receiving interleukin 2', AIDS Research and Human Retroviruses, vol. 18, no. 9, pp. 661-665. https://doi.org/10.1089/088922202760019365
Sha, Beverly E. ; Ogata-Arakaki, Debra M. ; Fox, Lawrence ; Estep, Scharla ; Erice, Alejo ; Kilgo, Patrick ; Pollard, Richard B ; Bancroft, Lynne ; Lederman, Michael M. ; Valdez, Hernan ; Gelman, Rebecca S. ; Landay, Alan L. ; Agosti, Jan ; Mitsuyasu, Ronald ; Pollard, Richard B. ; Mildvan, Donna ; Namkung, Ann. / Effect of etanercept (enbrel) on interleukin 6, tumor necrosis factor ", and markers of immune activation in HIV-infected subjects receiving interleukin 2. In: AIDS Research and Human Retroviruses. 2002 ; Vol. 18, No. 9. pp. 661-665.
@article{c7ee0fb04c5f48e5820086a5daccc318,
title = "Effect of etanercept (enbrel) on interleukin 6, tumor necrosis factor {"}, and markers of immune activation in HIV-infected subjects receiving interleukin 2",
abstract = "The effect of etanercept, a soluble p75 tumor necrosis factor (TNF) receptor:Fc fusion protein (Enbrel; Immunex, Seattle, WA) on plasma cytokines was evaluated in 11 HIV-infected subjects receiving highly active antiretroviral therapy (HAART) for 28 weeks with or without subcutaneous or intravenous recombinant human interleukin 2 (rhIL-2). Plasma IL-6 and C-reactive protein (CRP) levels increased after rhIL-2 treatment. Etanercept pretreatment attenuated these increases. Median plasma IL-6 levels were 20.29 pg/ml 4 days after rhIL-2 and 7.87 pg/ml 4 days after etanercept and rhIL-2 (p = 0.22); median CRP levels were 78.73 and 46.16 μg/ml, respectively (p = 0.03). An effect on TNF bioactivity could not be assessed as all measurements were below limits of detection. No significant changes were seen in temperature or plasma levels of IL-4, IL-l0, IL-12, interferon γ, or HIV-1 RNA levels. All subjects had undetectable or low-level HIV-1 RNA levels before etanercept dosing. One subject died; however, her death was thought to be unrelated to etanercept. Pretreatment with etanercept may blunt activation of IL-6 and CRP expression induced by rhIL-2. The safety and utility of etanercept in HIV-infected persons should be explored further.",
author = "Sha, {Beverly E.} and Ogata-Arakaki, {Debra M.} and Lawrence Fox and Scharla Estep and Alejo Erice and Patrick Kilgo and Pollard, {Richard B} and Lynne Bancroft and Lederman, {Michael M.} and Hernan Valdez and Gelman, {Rebecca S.} and Landay, {Alan L.} and Jan Agosti and Ronald Mitsuyasu and Pollard, {Richard B.} and Donna Mildvan and Ann Namkung",
year = "2002",
doi = "10.1089/088922202760019365",
language = "English (US)",
volume = "18",
pages = "661--665",
journal = "AIDS Research and Human Retroviruses",
issn = "0889-2229",
publisher = "Mary Ann Liebert Inc.",
number = "9",

}

TY - JOUR

T1 - Effect of etanercept (enbrel) on interleukin 6, tumor necrosis factor ", and markers of immune activation in HIV-infected subjects receiving interleukin 2

AU - Sha, Beverly E.

AU - Ogata-Arakaki, Debra M.

AU - Fox, Lawrence

AU - Estep, Scharla

AU - Erice, Alejo

AU - Kilgo, Patrick

AU - Pollard, Richard B

AU - Bancroft, Lynne

AU - Lederman, Michael M.

AU - Valdez, Hernan

AU - Gelman, Rebecca S.

AU - Landay, Alan L.

AU - Agosti, Jan

AU - Mitsuyasu, Ronald

AU - Pollard, Richard B.

AU - Mildvan, Donna

AU - Namkung, Ann

PY - 2002

Y1 - 2002

N2 - The effect of etanercept, a soluble p75 tumor necrosis factor (TNF) receptor:Fc fusion protein (Enbrel; Immunex, Seattle, WA) on plasma cytokines was evaluated in 11 HIV-infected subjects receiving highly active antiretroviral therapy (HAART) for 28 weeks with or without subcutaneous or intravenous recombinant human interleukin 2 (rhIL-2). Plasma IL-6 and C-reactive protein (CRP) levels increased after rhIL-2 treatment. Etanercept pretreatment attenuated these increases. Median plasma IL-6 levels were 20.29 pg/ml 4 days after rhIL-2 and 7.87 pg/ml 4 days after etanercept and rhIL-2 (p = 0.22); median CRP levels were 78.73 and 46.16 μg/ml, respectively (p = 0.03). An effect on TNF bioactivity could not be assessed as all measurements were below limits of detection. No significant changes were seen in temperature or plasma levels of IL-4, IL-l0, IL-12, interferon γ, or HIV-1 RNA levels. All subjects had undetectable or low-level HIV-1 RNA levels before etanercept dosing. One subject died; however, her death was thought to be unrelated to etanercept. Pretreatment with etanercept may blunt activation of IL-6 and CRP expression induced by rhIL-2. The safety and utility of etanercept in HIV-infected persons should be explored further.

AB - The effect of etanercept, a soluble p75 tumor necrosis factor (TNF) receptor:Fc fusion protein (Enbrel; Immunex, Seattle, WA) on plasma cytokines was evaluated in 11 HIV-infected subjects receiving highly active antiretroviral therapy (HAART) for 28 weeks with or without subcutaneous or intravenous recombinant human interleukin 2 (rhIL-2). Plasma IL-6 and C-reactive protein (CRP) levels increased after rhIL-2 treatment. Etanercept pretreatment attenuated these increases. Median plasma IL-6 levels were 20.29 pg/ml 4 days after rhIL-2 and 7.87 pg/ml 4 days after etanercept and rhIL-2 (p = 0.22); median CRP levels were 78.73 and 46.16 μg/ml, respectively (p = 0.03). An effect on TNF bioactivity could not be assessed as all measurements were below limits of detection. No significant changes were seen in temperature or plasma levels of IL-4, IL-l0, IL-12, interferon γ, or HIV-1 RNA levels. All subjects had undetectable or low-level HIV-1 RNA levels before etanercept dosing. One subject died; however, her death was thought to be unrelated to etanercept. Pretreatment with etanercept may blunt activation of IL-6 and CRP expression induced by rhIL-2. The safety and utility of etanercept in HIV-infected persons should be explored further.

UR - http://www.scopus.com/inward/record.url?scp=0036434120&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036434120&partnerID=8YFLogxK

U2 - 10.1089/088922202760019365

DO - 10.1089/088922202760019365

M3 - Article

VL - 18

SP - 661

EP - 665

JO - AIDS Research and Human Retroviruses

JF - AIDS Research and Human Retroviruses

SN - 0889-2229

IS - 9

ER -